<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1302233235
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        COSOPT EYE DROPS
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        DORZOLAMIDE,TIMOLOL MALEATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        2,0.5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        %
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Ocular use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Eye drops, solution
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Dropper Container
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        46.55
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="FAREVA MIRABEL" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            FAREVA MIRABEL
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 583]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ALNAGHI COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            MUNDIPHARMA PTY LTD
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        S01ED51
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>COSOPT contains two medicines: dorzolamide and timolol.</strong></p><ul><li>Dorzolamide belongs to a group of medicines called &ldquo;carbonic anhydrase inhibitors&rdquo;.</li><li>Timolol belongs to a group of medicines called &ldquo;beta blockers&rdquo;.</li></ul><p>These medicines lower the pressure in the eye in different ways.<br />COSOPT is prescribed to lower raised pressure in the eye in the treatment of glaucoma when<br />beta-blocker eyedrop medicine used alone is not adequate.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use COSOPT</strong></p><ul><li>&nbsp;if you are allergic to dorzolamide hydrochloride, timolol maleate or any of the other ingredients of this medicine (listed in section 6).</li><li>&nbsp;if you have now or had in the past respiratory problems, such as asthma or severe chronic obstructive bronchitis (severe lung disease which may cause wheeziness, dificulty in breathing and/or long-standing cough).</li><li>&nbsp;if you have a slow heart beat, heart failure or disorders of heart rhythm (irregular heart beats).</li><li>if you have severe kidney disease or problems, or a prior history of kidney stones.</li><li>if you have excess acidity of the blood caused by a build up of chloride in the blood hyperchloraemic acidosis).</li></ul><p>If you are not sure whether you should use this medicine, contact your doctor or pharmacist.</p><p><strong>Warnings and precautions</strong></p><ul><li>Talk to your doctor before using COSOPT.</li><li>Tell your doctor about any medical or eye problems you have now or have had in the past:</li><li>coronary heart disease (symptoms can include chest pain or tightness, breathlessness, or choking), heart failure, low blood pressure.</li><li>disturbances of heart rate such as slow heart beat.</li><li>&nbsp;breathing problems, asthma or chronic obstructive pulmonary disease.</li><li>poor blood circulation disease (such as Raynaud&rsquo;s disease or Raynaud&rsquo;s syndrome).</li><li>diabetes as timolol may mask signs and symptoms of low blood sugar.</li><li>overactivity of the thyroid gland as timolol may mask signs and symptoms.</li></ul><p>Tell your doctor before you have an operation that you are using COSOPT as timolol may change effects of some medicines used during anaesthesia.</p><p><br />Also tell your doctor about any allergies or allergic reactions including hives, swelling of the face, lips, tongue, and/or throat which may cause difficulty in breathing or swallowing.<br />Tell your doctor if you have muscle weakness or have been diagnosed as having myasthenia gravis.</p><p><br />If you develop any eye irritation or any new eye problems such as redness of the eye or swelling of the eyelids, contact your doctor immediately.<br />If you suspect that COSOPT is causing an allergic reaction or hypersensitivity (for example, skin rash, severe skin reaction, or redness and itching of the eye), stop using this medicine and contact your doctor immediately.</p><p><br />Tell your doctor if you develop an eye infection, receive an eye injury, have eye surgery, or develop a reaction including new or worsening symptoms.<br />When COSOPT is instilled into the eye it may affect the entire body.<br />If you wear soft contact lenses, you should consult your doctor before using this medicine.</p><p><br /><strong><u>Use in children</u></strong><br />There is limited experience with COSOPT in infants and children.<br /><strong><u>Use in elderly</u></strong><br />In studies with COSOPT, the effects of this medicine were similar in both elderly and younger patients.<br /><strong><u>Use in patients with liver impairment</u></strong><br />Tell your doctor about any liver problems you now have or have suffered from in the past.</p><p><strong>Other medicines and COSOPT</strong><br />COSOPT can affect or be affected by other medicines you are using, including other eye drops for the<br />treatment of glaucoma. Tell your doctor if you are using or intend to use medicines to lower blood<br />pressure, heart medicine or medicines to treat diabetes. Tell your doctor or pharmacist if you are using,<br />have recently used or might use any other medicines. This is particularly important if you are;</p><ul><li>taking medicine to lower blood pressure or to treat heart disease (such as calcium channel blockers, beta-blockers or digoxin).</li><li>taking medicines to treat a disturbed or irregular heartbeat such as calcium channel blockers, beta-blockers or digoxin.</li><li>using another eyedrop that contains a beta-blocker.</li><li>taking another carbonic anhydrase inhibitor such as acetazolamide.</li><li>taking monoamine oxidase inhibitors (MAOIs).</li><li>taking a parasympathomimetic medicine which may have been prescribed to help you pass urine.</li><li>Parasympathomimetics are also a particular type of medicine which is sometimes used to help restore normal movements through the bowel.</li><li>taking narcotics such as morphine used to treat moderate to severe pain.</li><li>taking medicines to treat diabetes.</li><li>taking antidepressants known as fluoxetine and paroxetine.</li><li>taking a sulfa medicine.</li><li>taking quinidine (used to treat heart conditions and some types of malaria).</li></ul><p><strong><u>Pregnancy and breast-feeding</u></strong><br />Ask your doctor or pharmacist for advice before taking any medicine.<br /><strong>Use in pregnancy</strong><br />Do not use COSOPT if you are pregnant unless your doctor considers it necessary.<br /><strong>Use in breast-feeding</strong><br />Do not use COSOPT if you are breast-feeding. Timolol may get into your milk. Ask your doctor for advice before taking any medicine during breast-feeding.</p><p><strong>Driving and using machines</strong><br />No studies on the effects on the ability to drive or use machines have been performed. There are side effects associated with COSOPT, such as blurred vision, which may affect your ability to drive and/or operate machinery. Do not drive or operate machinery until you feel well or your vision is clear.<br /><strong>COSOPT contains benzalkonium chloride</strong><br />If you wear soft contact lenses, you should consult your doctor before using COSOPT (the preservative benzalkonium chloride may possibly discolour the lenses).</p><p>Remove contact lenses prior to application and wait at least 15 minutes before reinsertion.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always use this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure. The appropriate this dosage and duration of treatment will be established by your doctor.</p><p><br />The recommended dose is one drop in the affected eye(s) in the morning and in the evening.<br />If you are using this medicine with another eye drop, the drops should be instilled at least 10 minutes apart.<br />Do not change the dose of the medicine without consulting your doctor.</p><p>Do not allow the tip of the container to touch the eye or areas around the eye. It may become contaminated with bacteria that can cause eye infections leading to serious damage of the eye, even loss of vision. To avoid possible contamination of the container, wash your hands before using this medicine and keep the tip of the container away from contact with any surface. If you think your medication may be contaminated, or if you develop an eye infection, contact your doctor immediately concerning continued use of this bottle.</p><p><u><strong>Instructions for use</strong></u><br />1. Before using the medication for the first time, be sure the Safety Strip on the front of the bottle is unbroken. A gap between the bottle and the cap is normal for an unopened bottle.</p><p>2. First wash your hands, then tear off the Safety Strip to break the seal.</p><p>3. To open the bottle, unscrew the cap by turning as indicated by the arrows on the top of the cap.Do not pull the cap directly up and away from the bottle. Pulling the cap directly up will prevent your dispenser from operating properly.</p><p>4. Tilt your head back and pull your lower eyelid down slightly to form a pocket between your eyelid and your eye.</p><p>5. Invert the bottle, and press lightly with the thumb or index finger over the &ldquo;Finger Push Area&rdquo; (as shown) until a single drop is dispensed into the eye as directed by your doctor.</p><p>6. After using COSOPT press a finger into the corner of your eye, by the nose, or close your eyelids for 2 minutes. This helps to stops the medicine from getting into the rest of the body.</p><p>7. If drop dispensing is difficult after opening for the first time, replace the cap on the bottle and tighten (Do not overtighten) and then remove by turning the cap in the opposite directions as indicated by the arrows on the top of the cap.<br />8. Repeat steps 4 &amp; 5 with the other eye if instructed to do so by your doctor.<br />9. Replace the cap by turning until it is firmly touching the bottle. The arrow on the left side of the cap must be aligned with the arrow on the left side of the bottle label for proper closure. Do not overtighten or you may damage the bottle and cap.<br />10. The dispenser tip is designed to provide a single drop; therefore, do NOT enlarge the hole of the dispenser tip.<br />11. After you have used all doses, there will be some COSOPT left in the bottle. You should not be concerned since an extra amount of this medicine has been added and you will get the full amount of COSOPT that your doctor prescribed. Do not attempt to remove the excess medicine from the bottle.</p><p><strong>If you use more COSOPT than you should</strong><br />If you put too many drops in your eye or swallow any of the contents of the container, among other effects, you may become light-headed, have difficulty breathing, or feel that your heart rate has slowed. Contact your doctor immediately.</p><p><br /><strong>If you forget to use COSOPT</strong><br />It is important to take this medicine as prescribed by your doctor.<br />If you miss a dose, use it as soon as possible. However, if it is almost time for the next dose, skip the missed dose and go back to your regular dosing schedule.<br />Do not take a double dose to make up for the forgotten dose.</p><p><strong>If you stop using COSOPT</strong></p><p>If you want to stop using this medicine talk to your doctor first.<br />If you have any further questions on the use of this product, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><br />You can usually carry on taking the drops, unless the effects are serious. If you&#39;re worried, talk to a doctor or pharmacist. Do not stop using COSOPT without speaking to your doctor.</p><p><br />Generalized allergic reactions including swelling beneath the skin that can occur in areas such as the face and limbs, and can obstruct the airway which may cause difficulty swallowing or breathing, hives or itchy rash, localized and generalized rash, itchiness, severe sudden life-threatening allergic reaction.</p><p>The frequency of possible side effects listed below is defined using the following convention:<br />Very common (affects more than 1 user in 10)<br />Common (affects 1 to 10 users in 100)<br />Uncommon (affects 1 to 10 users in 1,000)<br />Rare (affects 1 to 10 users in 10,000)<br />Not known (frequency cannot be estimated from the available data)</p><p>The following adverse reactions have been reported with COSOPT or one of its components either<br />during clinical trials or during post-marketing experience:</p><p>&nbsp;</p><p><u>Very Common:</u><br />Burning and stinging of the eyes, taste perversion<br /><u>Common:</u><br />Redness in and around the eye(s), watering or itching of the eye(s), corneal erosion (damage to the front layer of the eyeball), swelling and/or irritation in and around the eye(s), feeling of having something in the eye, decreased corneal sensitivity (not realizing of getting something in the eye and not feeling pain), eye pain, dry eyes, blurred vision, headache, sinusitis (feeling of tension or fullness in the nose), nausea, weakness/tiredness, and fatigue</p><p><u>Uncommon:</u><br />Dizziness, depression, inflammation of the iris, visual disturbances including refractive changes (due<br />to withdrawal of miotic therapy in some cases), slow heartbeat, fainting, difficulty breathing<br />(dyspnoea), indigestion, and kidney stones</p><p><u>Rare:</u><br />Systemic lupus erythematosus (an immune disease which may cause an inflammation of internal organs), tingling or numbness of the hands or feet, insomnia, nightmares, memory loss, an increase in signs and symptoms of myasthenia gravis (muscle disorder), decreased sex drive, stroke, temporary short sightedness which may resolve when treatment is stopped, detachment of the layer below the retina that contains blood vessels following from filtration surgery which may cause visual<br />disturbances, drooping of the eyelids (making the eye stay half closed), double vision, eyelid crusting, swelling of the cornea (with symptoms of visual disturbances), low pressure in the eye, ringing noises in your ear, low blood pressure, changes in the rhythm or speed of the heartbeat, congestive heart failure (heart disease with shortness of breath and swelling of feet and legs due to fluid build up), oedema (fluid build up), cerebral ischaemia (reduced blood supply to the brain), chest pain, palpitations (a quicker and/or irregular heartbeat), heart attack, Raynaud&#39;s phenomenon, swelling or coldness of your hands and feet and reduced circulation in your arms and legs, leg cramps and/or leg pain when walking (claudication), shortness of breath, impaired lung function, runny or stuffed nose, nose bleed, constriction of the airways in the lungs, cough, throat irritation, dry mouth, diarrhoea, contact dermatitis, hair loss, skin rash with white silvery coloured appearance (psoriasiform rash),</p><p>Peyronie&rsquo;s disease (which may cause a curvature of the penis), allergic type reactions such as rash, hives, itching, in rare cases possible swelling of the lips, eyes and mouth, wheezing, or severe skin<br />reactions (Stevens Johnson syndrome, toxic epidermal necrolysis). Like other medicines applied into your eyes, timolol is absorbed into the blood. This may cause similar side effects as seen with oral beta-blocking agents. Incidence of side effects after topical ophthalmic administration is lower than when medicines are, for example, taken by mouth or injected. Listed additional side effects include reactions seen within the class of beta-blockers when used for treating eye conditions.</p><p><u>Not known:</u><br />Low blood glucose levels, heart failure, a type of heart rhythm disorder, abdominal pain, vomiting, muscle pain not caused by exercise, sexual dysfunction.</p><p><strong>Reporting of side effects</strong><br />If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via &ldquo;The National Pharmacovigilance and Drug Safety Centre (NPC), SFDA&rdquo;. By reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.<br />Store below 30&deg;C<br />Store in the original package in order to protect from light.</p><p><br />Do not use this medicine after the expiry date shown by the six digits following EX (or EXP) on the container. The first two digits indicate the month; the last four digits indicate the year. The expiry date refers to the last day of that month.<br />You can use COSOPT for 28 days after first opening the container.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What COSOPT contains</strong></p><ul><li>&nbsp;The active substances are dorzolamide and timolol.Each ml contains 20 mg of dorzolamide (as 22.26 mg dorzolamide hydrochloride) and 5 mg of timolol (as 6.83 mg timolol maleate).</li><li>&nbsp;The other ingredients are Sodium Citrate Dihydrate (2.94 mg) ,Hydroxyethyl Cellulose (4.75 mg), Mannitol (16 mg), Sodium Hydroxide (qs pH=5.6), and Water for injection (qs 1 ml).Benzalkonium chloride is added as a preservative (0.075 mg).</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                COSOPT is a clear, colourless to nearly colourless slightly viscous solution. The OCUMETER Plus Ophthalmic Dispenser consists of a translucent, high-density polyethylene container containing 5 ml of solution. Tamper evidence is provided by a safety strip on the container label.
Pack sizes:
1 x 5 ml (single 5 ml containers)
3 x 5 ml (three 5 ml containers)
6 x 5 ml (six 5 ml containers)
Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder</strong><br />Merck Sharp &amp; Dohme B.V., Waarderweg 39,<br />2031 BN Haarlem, P.O. Box 581, 2003 PC Haarlem,<br />The Netherlands</p><p><br /><strong>Manufacturer</strong><br />Laboratoires Merck Sharp &amp; Dohme Chibret, Mirabel Plant, Route de Marsat, Riom, 63963 Clermont-Ferrand<br />Cedex 9 , France</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in March 2014.
Version No. (02)
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <ul><li dir="rtl">يحتوي عقار كوزوبت على علاجين: دورزولاميد وتيمولول.</li><li dir="rtl">ينتمي دورزولاميد إلى مجموعة من الأدوية تُسمى &quot;مثبطات الأنهيدرازُ الكَرْبُونِيَّة&quot;.&nbsp;</li></ul><p>ينتمي تيمولول إلى مجموعة من الأدوية تُسمى &quot;مثبطات بيتا&quot;. تخفض هذه الأدوية الضغط داخل العين بطرق مختلفة.&nbsp;</p><p>يُوصَف عقار كوزوبت لخفض الضغط المرتفع داخل العين أثناء علاج الزَرَق عندما يكون استخدام قطرة العين المحتوية على مثبطات بيتا وحدها غير كافي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا تستخدم عقار كوزوبت</p><ul><li>إذا كنت تعاني من حساسية تجاه دورزولاميد هيدروكلوريد أو تيمولول ماليات أو تجاه أي مكون من المكونات الأخرى لهذا الدَّواء (المذكورة في البند ٦)</li><li>إذا كنت تُعاني الآن أو عانيت في الماضي من مشاكل بالجهاز التنفسي،&nbsp;مثل الربو أو التهاب الشُعَب الهوائية الانسدادي المزمن الشديد (مرض شديد بالرئة قد يُسَبب أزيز بالصدر، صعوبة في التنفس و/أو سُعال لفترات طويلة)</li><li>إذا كنت تُعاني من بطء ضربات القلب أو فشل القلب أو اضطرابات بالنَظْم القلبي (عدم انتظام ضربات القلب)ز</li><li>إذا كنت تُعاني من مرض أو مشاكل شديدة بالكُلى، أو تاريخ مرضي سابق من حصى الكُلى.</li><li>إذا كنت تُعاني من زيادة حموضة الدم الناجمة عن تراكم الكلوريد في الدم.&nbsp;<br />(حمَُاض بفَرْطِ كلوريد الدَّمِ).</li></ul><p>إذا كنت غير متأكد مما إذا كان عليك أن تستخدم هذا الدواء، يرجى ان تتصل بطبيبك أو الصيدلي.</p><p><strong>تحذيرات واحتياطات</strong><br />تحدث إلى طبيبك قبل تناول كوزوبت.<br />اخبر طبيبك بشأن أي مشاكل طبية أو مشاكل بالعين تُعاني منها الآن أو قد عانيت منها في الماضي:</p><ul><li>أمراض الشرايين التاجية بالقلب )قد تشمل الأعراض ألم أو ضيق بالصدر أو عُسْر التَّ نَ فُّس أو اختناق(، قصور القلب،&nbsp;انخفاض ضغط الدم.اضطرابات بمعدل ضربات القلب مثل بطء ضربات القلب.&nbsp;</li><li>مشاكل بالتنفس، ربو أو مرض الانسداد الرئوي المزمن.&nbsp;</li><li>مرض ضعف الدورة الدموية(مثل: مرض رينود أو متلازمة رينود).&nbsp;</li><li>مرض السُّكَّرِي لأن تيمولول قد يُُفي علامات وأعراض انخفاض نسبة السكر بالدم.&nbsp;</li><li>فرط نشاط الغدة الدرقية لأن تيمولول قد يُُفي العلامات والأعراض.</li></ul><p><br />اخبر طبيبك قبل أن تخضع إلى عملية جراحية أنك تستخدم كوزوبت لأن تيمولول قد يُغرير من تأثيرات بعض الأدوية المستخدَمة أثناء التخدير.<br />اخبر طبيبك أيضًا بشأن أي حساسية أو تفاعلات حساسية بما في ذلك الشرى، تورُّم الوجه، والشفتين، واللسان و/أو الحَلْق الذي قد يُسَبب صعوبة في التنفس أو البلع.<br />اخبر طبيبك إذا كنت تُعاني من ضعف العضلات أو تم تشخيص إصابتك بالوهن العضلي الوبيل.<br />إذا أُصِبت بأي تهيُّج بالعين أو مشاكل جديدة بالعين مثل احمرار العين أو تورم الجفون، فاتصل بطبيبك على الفور.<br />إذا ساورك الشك بأن كوزوبت يُسَبب تفاعلات حساسية أو فرط الحساسية )على سبيل المثال: طفح جلدي أو تفاعل جلدي شديد أو احمرار<br />وحكة بالعين(، فتوقف عن استخدام هذا الدواء واتصل بطبيبك على الفور.<br />اخبر طبيبك إذا أُصِبت بعدوى في العين، أو عانيت من إصابة بالعين، أو خضعت لجراحة بالعين، أو أُصِبت بتفاعل يشمل أعراض جديدة<br />أو متفاقمة.<br />عند وضع قطرة من كوزوبت داخل العين فقد يؤثر على الجسم بالكامل.<br />إذا كنت ترتدي عدسات لاصقة لينة، فيجب استشارة طبيبك قبل استخدام هذا الدواء.</p><p><u>الاستخدام في الأطفال</u><br />هناك معلومات مُدودة بشأن استخدام كوزوبت في الرُضَّع والأطفال.<br /><u>الاستخدام في كبار السن</u><br />في الدراسات التي أُجريَّت على كوزوبت، كان تأثير هذا الدواء مماثلاً في كل من المرضى من كبار السن والأصغر سنًا.</p><p><u>الاستخدام في المرضى المصابين بقصور في الكبد</u><br />اخبر طبيبك بشأن أي مشاكل بالكبد تُعاني منها الآن أو قد عانيت منها في الماضي.</p><p><br /><strong>تناوُل كوزوبت مع أدوية أخرى</strong><br />يُُكِن أن يؤثر كوزوبت أو يتأثر بالأدوية الأخرى التي تستخدمها، بما في ذلك قطرات العين الأخرى الخاصة بعلاج الماء الأزرق في العين )إرتفاع الضغط العين(. اخبر طبيبك إذا كنت تستخدم أو تنوي استخدام أدوية أخرى لخفض ضغط الدَّم أو أدوية أمراض القلب أو أدوية لعلاج مرض<br />السُّكَّرِي. يُرجى إبلاغ الطبيب أو الصيدلي الخاص بك إذا كنت تستخدم أو استخدمت مؤخرًا أو قد تستخدم أيَّة أدوية أخرى. ي عَُد هذا هامًا بشكل خاص إذا:</p><ul><li>كنت تتناول دواء لخفض ضغط الدَّم أو لعلاج مرض بالقلب (مثل: مثبطات قنوات الكالسيوم أو مثبطات بيتا أو يجوكسِين).</li><li>كنت تتناول أدوية لعلاج اضطراب أو عدم انتظام ضربات القلب مثل: مثبطات قنوات الكالسيوم أو مثبطات بيتا أو ديجوكسِين.</li><li>كنت تستخدم قطرة عين أخرى تحتوي على أحد مثبطات بيتا.&nbsp;</li><li>كنت تتناول مثبط آخر لإنزيم الأنهيدرازُ الكَرْبُونِيَّ مثل: أسيتازولاميد.</li><li>&quot; كنت تتناول مثبطات أوكسيديز أحادي الأمين (مثبطات MOA)</li><li>كنت تتناول دواء مُُاكِي اللاوُردي والذي قد يُوصَف لمساعدتك على التبول.&nbsp;تعَُد مُُاكِيات اللاوُردي أيضًا نوع خاص من الأدوية التي تُستخدَم في بعض الأحيان للمساعدة على استعادة الحركة الطبيعية للأمعاء.</li><li>كنت تتناول الأدوية المخدرة&nbsp;مثل:عقار مورفين الذي يُستخدَم لعلاج&nbsp;الألم المعتدل الى الشديد.</li><li>كنت تتناول أدوية لعلاج مرض السُّكَّرِي.&nbsp;</li><li>كنت تتناول مضادات الاكتئاب المعروفة باسم فلوكسيتين وباروكسيتين.&nbsp;</li><li>كنت تتناول أحد الأدوية المحتوية على سَلْفا.&nbsp;</li><li>كنت تتناول كينيدين (يُستخدَم لعلاج حالات القلب وبعض أنواع الملاريا).</li></ul><p><strong>الحمل والرضاعة الطبيعية</strong><br />استشيري طبيبكِ أو الصيدلي قبل تناول أي دواء.<br /><u>الاستخدام أثناء الحمل</u><br />لا تستخدمي كوزوبت إذا كنتِ حاملاً ما لم ير طبيبك ضرورة لاستخدامه.<br /><u>الاستخدام أثناء الرضاعة الطبيعية</u><br />لا تستخدمي كوزوبت إذا كنتِ تمارسين الرضاعة الطبيعية. قد يصل عقار تيمولول إلى لبن الأم. استشيري طبيبكِ أو الصيدلي قبل تناول أي دواء أثناء الرضاعة الطبيعية.</p><p><strong>القيادة واستخدام الآلات</strong><br />لم يتم إجراء أيَّة دراسات بشأن التأثيرات في القدرة على قيادة أو استخدام الآلات. هناك آثار جانبية مُصاحِبة لاستخدام كوزوبت، مثل عدم وضوح الرؤية، التي قد تؤثر على قدرتك على القيادة و/أو تشغيل الآلات. لا تقم بالقيادة أو تشغيل الآلات حتى تشعر بأنك على ما يرام أو<br />أن الرؤية واضحة لك.</p><p><strong>يحتوي كوزوبت على كلوريد البنزالكونيوم</strong><br />إذا كنت ترتدي عدسات لاصقة لينة، فيجب استشارة طبيبك قبل استخدام كوزوبت (ربما قد تغير المواد الحافظة لكلوريد<br />البنزالكونيوم لون العدسات).<br />يجب إزالة العدسات اللاصقة قبل الاستخدام والانتظار 15 دقيقة على الأقل قبل إعادة وضعها.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>استخدم دائمًا هذا الدَّواء بالضبط كما أخبرك طبيبك. يُرجى مراجعة الطبيب أو الصيدلي إذا لم تكن متأكدًا. سيتأكد طبيبك من الجرعة ومدة العلاج المناسبة لك.<br />الجرعة الموصى بها هي قطرة واحدة في العين (العينين)المصابة (المصابتين)في الصباح وفي المساء.<br />إذا كنت تستخدم هذا الدواء مع قطرة عين أخرى، فيجب الفصل بين القطرات بفاصل ۱۰ دقائق على الأقل.</p><p>لا تُغرير جرعة الدواء دون استشارة طبيبك.</p><p>لا تسمح لطرف الحاوية أن يلمس العين أو المناطق المحيطة بها. فقد تصبح ملوثة بالبكتيريا التي يُُكِن أن تُسَبب عدوى بالعين تؤدي إلى ضرر خطير بالعين، يصل إلى فقدان الرؤية. لتجنُّب إمكانية حدوث تلوث للحاوية، اغسل يديك قبل استخدام هذا الدواء وتجنب أن يلمس طرف<br />الحاوية أي سطح. إذا اعتقدت أن الدواء قد يكون ملوثًا، أو إذا أُصِبت بعدوى في العين، فاتصل بطبيبك على الفور واسأله بشأن مواصلة استخدام هذه الزجاجة.</p><p><strong>تعليمات الاستعمال</strong></p><ol><li>قبل استخدام الدواء لأول مرة، تأكد من أن شريط الأمان الموجود على الزجاجة غير ممزق. وجود فجوة بين الزجاجة والغطاء أمر طبيعي بالنسبة إلى الزجاجة التي لم يتم فتحها.</li><li>&nbsp;اغسل يديك أولاً، ثم انزع شريط الأمان لإزالة الخَتْم.</li><li>لفتح الزجاجة، فك الغطاء عن طريق اللف على النحو الموضَّح بالأسهم الموجودة أعلى الغطاء.</li><li>قم بإمالة رأسك إلى الخلف مع شد الجفن السفلي لأسفل قليلاً لتشكيل جيب بين الجفن والعين.</li><li>اقلب الزجاجة، ثم اضغط برفق بالإبهام أو السبابة على &quot;منطقة دفع الإصبع&quot;(على النحوالموضَّح)حتى يتم توزيع قطرة واحدة في العين&nbsp;حسب توجيهات طبيبك.</li><li>بعد استخدام كوزوبت اضغط بأصبعك في الركن الواقع بين العين والأنف، أو اغلق جفنيك لمدة دقيقتين. يساعد هذا على إيقاف وصول الدواء إلى باقي الجسم.</li><li>إذا كان توزيع القطرة صعبًا بعد فتحها لأول مرة، فأعِد وضع الغطاء على الزجاجة وأحكم تثبيته(لا تبالغ في تثبيته) ثم انزعه عن&nbsp;طريق لف الغطاء في الاتجاه المعاكس على النحو الموضَّح بالأسهم الموجودة أعلى الغطاء.</li><li>اعِد الخطوات ٤ و ٥ بالعين الأخرى إذا طلب منك طبيبك القيام بذلك.</li><li>اعِد وضع الغطاء عن طريق اللف حتى تلامس الزجاجة بإحكام. يجب مُاذاة السهم الموجود على الجانب الأيسر من الغطاء بالسهم الموجود على الجانب الأيسر من مُلصَق الزجاجة حتى تُغلَق بشكل سليم. لا تبالغ في التثبيت بإحكام وإلا قد تتلف الزجاجة والغطاء.</li><li>طرف الموزع مُصَمَم ليُخرِج قطرة واحدة؛ لذا، لا تقم بتكبير الثقب الموجود بطرف الموزع.</li><li>بعد استخدامك لجميع الجرعات، سيتبقى بعض من عقار كوزوبت في الزجاجة. يجب ألا تقلق بسبب إضافة كمية إضافية من هذا الدواء وستحصل على الكمية الكاملة من عقار كوزوبت التي وصفها لك طبيبك. لا تحاول اخراج الدواء الزائد من الزجاجة.</li></ol><p>&nbsp;</p><p><strong>إذا استخدمت كمية من كوزوبت أكثر مما يجب</strong><br />إذا وضعت كمية قطرات كبيرة جدًا في عينك أو ابتلعت أي من المحتويات الموجودة بالحاوية، من بين آثار أخرى، قد تشعر بخفة الرأس، صعوبة في التنفس، أو تشعر بأن معدل ضربات القلب قد تباطأ. يرجى الاتصال بالطبيب فورا.</p><p><strong>إذا استخدمت تناوُل كوزوبت</strong><br />من المهم أن تستخدم هذا الدواء على النحو الذي وصفه لك طبيبك.<br />إذا نسيت تناول إحدى الجرعات، فتناولها بأسرع ما يُكن. ومع ذلك، إذا كان موعد تناوُل الجرعة التالية، فتجاوز الجرعة التي أغفلتها واستمر في استخدام الجرعات بشكل منتظم وفقًا لجدولك المعتاد</p><p>لا تستخدم جرعة مضاعفة لتعويض جرعة نسيتها.</p><p><strong>إذا توقفت عن تناول كوزوبت</strong><br />إذا أردت التوقف عن استخدام هذا الدواء، فتحدَّث إلى الطبيب أولا.<br />إذا كانت لديكِ أية أسئلة إضافية حول استخدام هذا المنتج، فاستشير طبيبكِ أو الصيدلي الخاص بك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثله مثل كافة الأدوية، قد يُسبب هذا الدَّواء آثارًا جانبية، على الرغم من عدم حدوثها لدى الجميع.</p><p>يُُكِنك عادة مواصلة استخدام القطرات، ما لم تحدث آثار خطيرة. إذا شعرت بالقلق، فتحدَّث إلى الطبيب أو الصيدلي. لا تتوقف عن استخدام كوزوبت دون التحدُّث إلى طبيبك.<br />تفاعلات حساسية متعممة )عامة( تشمل تورُّم أسفل الجلد يُُكِن أن يحدث في مناطق مثل الوجه والأطراف، ويُُكِن أن يُعيق المسلك الهوائي مما قد يُسَبب صعوبة في البلع أو التنفس، شرى أو طفح جلدي مصحوب بحكة، طفح جلدي موضعي ومُعَمم، حكة، تفاعلات حساسية شديدة ومفاجئة ومُهَددة للحياة.</p><p>يعرف معدل تكرار الآثار الجانبية المحتملة المدرجة أدناه باستخدام الاصطلاحات التالية:</p><p>شائعة جدًا (تؤثر على أكثر من مستخدم واحد من بين كل ۱۰ مستخدمين)</p><p>شائعة (تؤثر على مستخدم واحد إلى ۱۰ مستخدمين من بين كل ۱۰۰ مستخدم،)</p><p>نادرة(تؤثر على مستخدم واحد إلى ۱۰ مستخدمين من بين كل ۱۰۰۰۰ مستخدم)<br />غير معروفة (لا يُكن تقدير معدل التكرار من واقع البيانات المتاحة)</p><p>تم الإبلاغ عن الآثار الجانبية التالية مع كوزوبت أو أحد مكوناته سواء أثناء التجارب السريرية أو أثناء خبرة ما بعد التسويق:</p><p><u>شائعة جدًّا:</u><br />حُرقة ولسع بالعينين، تغير حاسة التذوق<br /><u>شائعة:</u><br />احمرار في العين )العينين( أو حولها )حولهما(، إدماع أو حكة بالعين )بالعينين(، تآكل القرنية )تلف الطبقة الأمامية لمقلة العين(، تورُّم و/أوتهيُّج في العين )العينين( أو حولها )حولهما(، الشعور بوجود شيء ما في العين، انخفاض حساسية القرنية )عدم إدراك الإصابة بشئ ما في<br />العين وعدم الشعور بألم(، ألم بالعين، جفاف العينين، عدم وضوح الرؤية، صُداع، الْتِهابُ الجُيوب الأنفية )شعور بالتوتر والامتلاء فيالأنف(، غثيان، ضَعْف/ تعب، وإ رهاق<br /><u>غير شائعة:</u><br />دوخة، اكتئاب، التهاب القُزَحِيَّة، اضطرابات الرؤية بما فيها التغيرات الانْكِسارِيّة )نتيجة سحب العلاج القابض للحدقة في بعض الحالات(،بطء ضربات القلب، إغماء، صعوبة التنفس )ضيق التَّنفس(، عسر الهضم، وحصى الكُلى</p><p><u>نادرة:</u><br />الرذئْ بَةِ الحُمَامِ يَّةِ الجَهازِيَّة )مرض مناعي قد يُسَبب التهاب بالأعضاء الداخلية(، وخز أو تنميل باليدين أو القدمين، أَرَق، كوابيس، فقدان الذاكرة، زيادة في علامات وأعراض الوهن العضلي الوبيل )اضطراب عضلي(، انخفاض الرغبة الجنسية، سكتة دماغية، قصر نظر مؤقت قد يتم&nbsp;التعافي منه عند إيقاف العلاج، إنفصال الطبقة الموجودة أسفل الشبكية والتي تحتوي على الأوعية الدموية بعد جراحة الترشيح مما قد يسبباضطرابات بصرية، تدلى الجفون )يجعل العين نصف مغلقة(، ازدواج الرؤية، تقشُّر الجلد حول الجفن، تورُّم القرنية )مع أعراض الاضطراباتالبصرية(، انخفاض الضغط في العين، أصوات رنين في الأذن، انخفاض ضغط الدَّم، تغيرات في النظم القلبي وسرعة ضربات القلب، فشل القلب الاحتقاني )مرض بالقلب مصحوب بضيق النفس وتورُّم القدمين والساقين بسبب تراكم السوائل(، وذمة )تراكم السوائل(، إقفار المخ )انخفاض إمداد الدم للمخ(، ألم بالصدر، خَفَقان )ضربات قلب أسرع و/أو غير منتظمة(، نوبة قلبية، ظاهرة رينود، تورُّم وبرودة اليدين والقدمين وانخفاض الدورة الدموية في الذراعين والساقين، تقلص بعضلات الساق و/أو ألم بالساق عند السير )عَرَج(، ضيق النفس، قصور وظائف الرئة، رشح أو انسداد بالأنف، نزيف منالأنف، تضيُّق الشُعَب الهوائية في الرئتين، سُعال، تهيُّج الحَلْق، جفاف الفم، إسهال، التهاب الجلد التماسي، تساقط الشعر، طفح جلدي مع ظهور لون أبيض فضي )طفح جلدي شبيه بالصدفية(،</p><p>داء بِيروني )الذي قد يُسَبب اعوجاج العضو الذكري(، تفاعلات حساسية مثل: طفح جلدي، شرى )ارتكاريا(، حكة، وفي حالات نادرة من الممكِن الإصابة بتورُّم بالشفتين والعينين والفم، أزيز بالصدر، أو تفاعلات جلدية شديدة )متلازمة ستيفنز جونسون، انحلال البشرة النخري التَّسَمُّمِيّ(.</p><p>مثله مثل أدوية أخرى توضع في العينين، يتم امتصاص تيمولول في الدم. قد يُسَبب هذا آثار جانبية مماثلة لتلك التي يتم ملاحظتها مع استخدام مثبطات بيتا التي يتم تناوُلها عن طريق الفم. معدل حدوث آثار جانبية بعد الاستخدام الموضعي تكون أقل من تناوُل الأدوية على سبيل المثال، عن طريق الفم أو الحَقْن. الآثار الجانبية الإضافية المدرَجة تشمل التفاعلات التي تمت رؤيتها ضمن فئة مثبطات بيتا عند استخدامها لعلاج حالات العين.</p><p><u>غير معروفة:</u><br />انخفاض مستويات الجلوكوز بالدم، فشل القلب، أحد أنواع اضطراب النظم القلبي، ألم بالبطن، قيء، ألم بالعضلات غير ناجم عن ممارسة التمارين الرياضية، اختلال ال وظيفة الجنسية.</p><p><strong>الإبلاغ عن الآثار الجانبية</strong><br />تحدَّث إلى الطبيب أو الصيدلي إذا ظهرت لديك أية آثار جانبية. بما في ذلك أية آثار جانبية مُُتمَلة، غير المذكورة في هذه النَّشرة. يُكنكتلإبلاغ عن الآثار الجانبية عن طريق &quot; المركز الوطني للتيقظ والسلامة الدوائية&quot; الم ذكور في بند &quot; للإبلاغ عن الأعراض الجانبية&quot;. من خلال إبلاغك عن الآثار الجانبية، يُكنك المساعدة في توفير معلومات إضافية حول أمان استخدام هذا الدَّواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يُحفظ بعيدًا عن متناول أيدي ومرأى الأطفال.<br />يُحفظ في درجة حرارة أقل من ٣۰ درجة مئوية.<br />يُحفظ في العبوة الأصلية لحمايته من الضوء.</p><p>&nbsp;</p><p>لا تستعمل هذا الدَّواء بعد تاريخ انتهاء الصلاحية المكون من ٦ أرقام المدون على العبوة بعد كلمة&quot;EX&quot; او &quot;EXP&quot;يشير الرقمان&nbsp;الأولان إلى الشهر؛ وتشير الأرقام الأربعة الأخيرة إلى العام. يُشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p>لا يُُكِنك استخدام قطرات كوزوبت لمدة أكثر من ۲۸ يوم بعد فتح العبوة لأول مرة.</p><p>لا تتخلص من الأدوية عن طريق إلقائها في مياه الصرف أو مع المخلفات المنزلية. استشر الصيدلي الخاص بك عن كيفية التَّخلص من <strong>​​​​​​​​​​​​​​</strong>الأدوية التي لم تعد تستخدمها. سوف تُساعد هذه الإجراءات في الحفاظ على البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>ما هي محتويات عقار كوزوبت؟</strong></p><ul><li>المواد الفعالة هي دورزولاميد وتيمولول.&nbsp;يحتوي كل مل على 20 ملجم دورزولاميد (على هيئة 22.26 ملجم هيدروكلوريد دورزولاميد)و 5 ملجم تيمولول (على هيئة 6.83&nbsp;ملجم تيمولول ماليات).</li><li>المكونات الأخرى : سترات الصوديوم ثنائي الهيدرات( 2.94 ملغم)، هيدروكسي إيثيلِ السليلوز ( 4.75 ملغم(، مانيتول ) 16 ملغم)، ، هيدروكسيد الصوديوم (لغاية معامل الحموضة = 5،6 )، وماء للحقن (لغاية 1 مل). يضاف كلوريد البنزالكونيوم كمادة حافظة( 0.075 ملغم)، .</li></ul><p><strong>ما هو شكل كوزوبت؟ وما هي محتويات العبوة؟</strong><br />عقار كوزوبت هو محلول صاف، عديم اللون أو يقترب من انعدام اللون، لزج قليلاً. يتكون &quot;Plus OCUMETER&quot;موزع لمحلول العين من حاوية شفافة، عالية الكثافة من البولي إيثيلين تحتوي على 5 مل من المحلول. العبوة مزودة بدليل العبث في هيئة شريط أمان موجود&nbsp;على مُلصَق العبوة.<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:right"><strong>أحجام العبوة:</strong><br />1x5 (قارورة واحدة تحتوي على 5 مل)</p><p style="text-align:right">3x5 (ثلاث قوارير&nbsp;تحتوي على 5 مل)</p><p style="text-align:right">1x5 (ست&nbsp;قوارير&nbsp;تحتوي على 5 مل)</p><p style="text-align:right">قد لا يتم تسويق جميع أحجام العبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>مالك حقوق التَّسويق</strong><br />ميرك شارب و دوم بي. في.،<br />٢۰۰٣ بي سي هارلم ، واردرويج ٣٩ ، بي ان هارلم، ٢٠٣١ ، صندوق بريد ٥٨۱<br />هولندا<br /><strong>الشركة المصنعة:</strong><br />معامل شركة ميرك شارب و دوم شيبريت، ميرابيل بلانت،<br />طريق مارسات ، ريوم<br />٦٣٩٦٣ كليرمون فيران سيدكس ٩، فرنسا<br />.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت آخر مراجعة لهذه النشرة في ما رس 2014
 الاصدار رقم (2)
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                COSOPT 20 mg/ml + 5 mg/ml, eye drops, solution
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each ml contains 22.26 mg of dorzolamide hydrochloride corresponding to 20 mg dorzolamide and 6.83 mg of timolol maleate corresponding to 5 mg timolol.
Excipients: Benzalkonium chloride 0.075 mg/ml
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Eye drops, solution
Clear, colourless to nearly colourless, slightly viscous solution, with a pH between 5.5, and 5.8, and an osmolarity of 242-323 mOsM.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Indicated in the treatment of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or pseudoexfoliative glaucoma when topical beta-blocker monotherapy is not sufficient.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u><br />The dose is one drop of COSOPT in the (conjunctival sac of the) affected eye(s) two times daily.<br />If another topical ophthalmic agent is being used, COSOPT and the other agent should be administered at least ten minutes apart.<br />Patients should be instructed to wash their hands before use and avoid allowing the tip of the container to come into contact with the eye or surrounding structures.<br />Patients should also be instructed that ocular solutions, if handled improperly, can become contaminated by common bacteria known to cause ocular infections. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions.<br />Patients should be informed of the correct handling of the OCUMETER PLUS bottles.</p><p><u>Method of administration</u></p><ol><li>Before using the medication for the first time, be sure the Safety Strip on the front of the bottle is unbroken. A gap between the bottle and the cap is normal for an unopened bottle.</li><li>&nbsp;First wash your hands, then tear off the Safety Strip to break the seal.</li><li>To open the bottle, unscrew the cap by turning as indicated by the arrows on the top of the cap. Do not pull the cap directly up and away from the bottle. Pulling the cap directly up will prevent your dispenser from operating properly.</li><li>Tilt your head back and pull your lower eyelid down slightly to form a pocket between your eyelid and your eye.</li><li>Invert the bottle, and press lightly with the thumb or index finger over the &ldquo;Finger Push Area&rdquo; until a single drop is dispensed into the eye as directed by your doctor. DO NOT TOUCH YOUR EYE OR EYELID WITH THE DROPPER TIP.</li><li>When using nasolacrimal occlusion or closing the eyelids for 2 minutes, the systemic absorption is reduced. This may result in a decrease in systemic side effects and an increase in local activity.</li><li>If drop dispensing is difficult after opening for the first time, replace the cap on the bottle and btighten (Do not overtighten) and then remove by turning the cap in the opposite directions as indicated by the arrows on the top of the cap</li><li>Repeat steps 4 &amp; 5 with the other eye if instructed to do so by your doctor.</li><li>&nbsp;Replace the cap by turning until it is firmly touching the bottle. The arrow on the left side of the cap must be aligned with the arrow on the left side of the bottle label for proper closure.Do not overtighten or you may damage the bottle and cap.</li><li>The dispenser tip is designed to provide a single drop; therefore, do NOT enlarge the hole of the dispenser tip.</li><li>After you have used all doses, there will be some medicine left in the bottle. You should not be concerned since an extra amount of medicine has been added and you will get the full amount of COSOPT that your doctor prescribed. Do not attempt to remove the excess medicine from the bottle.</li></ol><p><em>Paediatric population</em></p><p><em>Efficacy in paediatric patients has not been established.<br />Safety in paediatric patients below the age of 2 years has not been established (For information regarding safety in paediatric patients &ge; 2 and &lt; 6 years of age, see section 5.1).</em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                COSOPT is contraindicated in patients with:
-reactive airway disease, including bronchial asthma or a history of bronchial asthma, or severe chronic obstructive pulmonary disease
-sinus bradycardia, sick sinus syndrome, sino-atrial block, second or third degree atrioventricular block not controlled with pacemaker, overt cardiac failure, cardiogenic shock
-severe renal impairment (CrCl < 30 ml/min) or hyperchloraemic acidosis
-hypersensitivity to one or both active substances or to any of the excipients listed in section 6.1.
The above are based on the components and are not unique to the combination.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Cardiovascular/Respiratory Reactions</u><br />Like other topically applied ophthalmic agents timolol is absorbed systemically. Due to betaadrenergic component, timolol, the same types of cardiovascular, pulmonary and other adverse reactions seen with systemic beta-adrenergic blocking agents may occur. Incidence of systemic ADRs after topical ophthalmic administration is lower than for systemic administration. To reduce the systemic absorption, see section 4.2.</p><p><em>Cardiac Disorders:</em><br />In patients with cardiovascular diseases (e.g. coronary heart disease, Prinzmetal&#39;s angina and cardiac failure) and hypotension therapy with beta-blockers should be critically assessed and the therapy with other active substances should be considered. Patients with cardiovascular diseases should be watched for signs of deterioration of these diseases and of adverse reactions.<br />Due to its negative effect on conduction time, beta-blockers should only be given with caution to patients with first degree heart block.</p><p><br /><em>Vascular Disorders:</em><br />Patients with severe peripheral circulatory disturbance/disorders (i.e. severe forms of Raynaud&rsquo;s disease or Raynaud&rsquo;s syndrome) should be treated with caution.</p><p><br /><em>Respiratory Disorders</em>:<br />Respiratory reactions, including death due to bronchospasm in patients with asthma have been reported following administration of some ophthalmic beta-blockers.<br />COSOPT should be used with caution, in patients with mild/moderate chronic obstructive pulmonary disease (COPD) and only if the potential benefit outweighs the potential risk.</p><p><em>Hepatic Impairment</em><br />This medicinal product has not been studied in patients with hepatic impairment and should therefore be used with caution in such patients.</p><p><em>Immunology and Hypersensitivity</em><br />As with other topically-applied ophthalmic agents, this medicinal product may be absorbed systemically. Dorzolamide contains a sulfonamido group, which also occurs in sulfonamides.<br />Therefore, the same types of adverse reactions found with systemic administration of sulfonamides may occur with topical administration, including severe reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis. If signs of serious reactions or hypersensitivity occur, discontinue use of this preparation.</p><p>Local ocular adverse effects, similar to those observed with dorzolamide hydrochloride eye drops,<br />have been seen with this medicinal product. If such reactions occur, discontinuation of this medicinal product should be considered.<br />While taking beta-blockers, patients with a history of atopy or a history of severe anaphylactic reaction to a variety of allergens may be more reactive to repeated challenge with such allergens and may be unresponsive to the usual dose of adrenaline used to treat anaphylactic reactions.</p><p>&nbsp;</p><p><em>Concomitant Therapy</em><br />The effect on intra-ocular pressure or the known effects of systemic beta-blockade may be potentiated when timolol is given to the patients already receiving a systemic beta-blocking agent. The response of these patients should be closely observed. The use of two topical beta-adrenergic blocking agents is not recommended (see section 4.5).<br />The use of dorzolamide and oral carbonic anhydrase inhibitors is not recommended.</p><p><u>Withdrawal of Therapy</u><br />As with systemic beta-blockers, if discontinuation of ophthalmic timolol is needed in patients with coronary heart disease, therapy should be withdrawn gradually.<br /><u>Additional Effects of Beta-Blockade</u><br /><em>Hypoglycaemia/diabetes:</em><br />Beta-blockers should be administered with caution in patients subject to spontaneous hypoglycaemia or to patients with labile diabetes, as beta-blockers may mask the signs and symptoms of acute hypoglycaemia.<br />Beta-blockers may also mask the signs of hyperthyroidism. Abrupt withdrawal of beta-blocker therapy<br />may precipitate a worsening of symptoms.</p><p><em>Corneal diseases</em><br />Ophthalmic beta-blockers may induce dryness of eyes. Patients with corneal diseases should be treated with caution.<br /><em>Surgical anaesthesia</em><br />Beta-blocking ophthalmological preparations may block systemic beta-agonist effects e.g. of adrenaline. The anaesthesiologist should be informed when the patient is receiving timolol.<br />Therapy with beta-blockers may aggravate symptoms of myasthenia gravis.</p><p>&nbsp;</p><p><u>Additional Effects of Carbonic Anhydrase Inhibition</u><br />Therapy with oral carbonic anhydrase inhibitors has been associated with urolithiasis as a result of acid-base disturbances, especially in patients with a prior history of renal calculi. Although no<br />acid-base disturbances have been observed with this medicinal product, urolithiasis has been reported infrequently. Because COSOPT contains a topical carbonic anhydrase inhibitor that is absorbed systemically, patients with a prior history of renal calculi may be at increased risk of urolithiasis while using this medicinal product.</p><p><u>Other</u><br />The management of patients with acute angle-closure glaucoma requires therapeutic interventions in addition to ocular hypotensive agents. This medicinal product has not been studied in patients with<br />acute angle-closure glaucoma.<br />Corneal oedema and irreversible corneal decompensation have been reported in patients with pre-existing chronic corneal defects and/or a history of intraocular surgery while using dorzolamide.<br />There is an increased potential for developing corneal oedema in patients with low endothelial cell counts. Precautions should be used when prescribing COSOPT to these groups of patients.<br />Choroidal detachment has been reported with administration of aqueous suppressant therapies (e.g. timolol, acetazolamide) after filtration procedures.</p><p>As with the use of other antiglaucoma medicines, diminished responsiveness to ophthalmic timolol maleate after prolonged therapy has been reported in some patients. However, in clinical studies in&nbsp;which 164 patients have been followed for at least three years, no significant difference in mean intraocular pressure has been observed after initial stabilization.</p><p><u>Contact Lens Use</u><br />This medicinal product contains the preservative benzalkonium chloride, which may cause eye irritation. Remove contact lenses prior to application and wait at least 15 minutes before reinsertion.<br />Benzalkonium chloride is known to discolour soft contact lenses.</p><p><u>Paediatric population</u><br />See section 5.1.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Specific medicine interaction studies have not been performed with COSOPT.</p><p>In clinical studies, this medicinal product was used concomitantly with the following systemic<br />medications without evidence of adverse interactions: ACE-inhibitors, calcium channel blockers,diuretics, non-steroidal anti-inflammatory medicines including aspirin, and hormones (e.g., estrogen, insulin, thyroxine).</p><p>There is a potential for additive effects resulting in hypotension and/or marked bradycardia when ophthalmic beta-blockers solution is administered concomitantly with oral calcium channel blockers, catecholamine-depleting medicines or beta-adrenergic blocking agents, antiarrhythmics (including amiodarone), digitalis glycosides, parasympathomimetics, guanethidine, narcotics, and monoamine oxidase (MAO) inhibitors.</p><p>Potentiated systemic beta-blockade (e.g., decreased heart rate, depression) has been reported during combined treatment with CYP2D6 inhibitors (e.g. quinidine, fluoxetine, paroxetine) and timolol.</p><p><br />Although COSOPT alone has little or no effect on pupil size, mydriasis resulting from concomitant use of ophthalmic beta-blockers and adrenaline (epinephrine) has been reported occasionally.</p><p>Beta-blockers may increase the hypoglycaemic effect of antidiabetic agents.<br />Oral beta-adrenergic blocking agents may exacerbate the rebound hypertension which can follow the withdrawal of clonidine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u><br />COSOPT should not be used during pregnancy.<br />Dorzolamide<br />No adequate clinical data in exposed pregnancies are available. In rabbits, dorzolamide produced teratogenic effect at maternotoxic doses (see section 5.3).</p><p><br />Timolol<br />There are no adequate data for the use of timolol in pregnant women. Timolol should not be used during pregnancy unless clearly necessary. To reduce the systemic absorption, see section 4.2.</p><p><br />Epidemiological studies have not revealed malformative effects but show a risk for intra uterine growth retardation when beta-blockers are administered by the oral route. In addition, signs and symptoms of beta-blockade (e.g. bradycardia, hypotension, respiratory distress and hypoglycaemia)have been observed in the neonate when beta-blockers have been administered until delivery.If this medicinal product is administered until delivery, the neonate should be carefully monitored during the first days of life.</p><p><u>Breast-feeding</u><br />It is not known whether dorzolamide is excreted in human milk. In lactating rats receiving dorzolamide, decreases in the body weight gain of offspring were observed. Beta-blockers are<br />excreted in breast milk. However, at therapeutic doses of timolol in eye drops it is not likely that sufficient amounts would be present in breast milk to produce clinical symptoms of beta-blockade in the infant. To reduce the systemic absorption, see section 4.2. If treatment with COSOPT is required, then lactation is not recommended.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed. Possible side effects such as blurred vision may affect some patients&rsquo; ability to drive and/or operate machinery</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In clinical studies for COSOPT the observed adverse reactions have been consistent with those that were reported previously with dorzolamide hydrochloride and/or timolol maleate.</p><p><br />During clinical studies, 1035 patients were treated with COSOPT. Approximately 2.4% of all patients discontinued therapy with this medicinal product because of local ocular adverse reactions,<br />approximately 1.2% of all patients discontinued because of local adverse reactions suggestive of allergy or hypersensitivity (such as lid inflammation and conjunctivitis).</p><p><br />Like other topically applied ophthalmic medicines, timolol is absorbed into the systemic circulation. This may cause similar undesirable effects as seen with systemic beta-blocking agents. Incidence of systemic ADRs after topical ophthalmic administration is lower than for systemic administration.</p><p><br />The following adverse reactions have been reported with COSOPT or one of its components either during clinical trials or during post-marketing experience:</p><p>[Very Common: (=&gt;1/10), Common: (=&gt;1/100 to &lt;1/10), Uncommon: (=&gt;1/1,000 to &lt;1/100), and Rare:<br />(=&gt;1/10.000to &lt;1/1,000), Not known (cannot be estimated from the available data)]</p><table border="1" cellspacing="1" cellpadding="1" style="width:1033px"><tbody><tr><td style="width:176px">System Organ<br />Class(MedDRA)</td><td style="width:166px"><br />Formulation Very<br />&nbsp;</td><td style="width:64px">Common<br />&nbsp;</td><td style="width:151px">Common</td><td style="width:87px">Uncommon</td><td style="width:187px">Rare</td><td style="width:204px">Not Known**</td></tr><tr><td style="width:176px">Immune system<br />disorders</td><td style="width:166px">COSOPT</td><td style="width:64px">&nbsp;</td><td style="width:151px">&nbsp;</td><td style="width:87px">&nbsp;</td><td style="width:187px">signs and<br />symptoms of<br />systemic<br />allergic<br />reactions,<br />including<br />angioedema,<br />urticaria,<br />pruritus, rash,<br />anaphylaxis</td><td style="width:204px">&nbsp;</td></tr><tr><td style="width:176px">&nbsp;</td><td style="width:166px">Timolol<br />maleate eye<br />drops, solution</td><td style="width:64px">&nbsp;</td><td style="width:151px">&nbsp;</td><td style="width:87px">&nbsp;</td><td style="width:187px">signs and<br />symptoms of<br />allergic<br />reactions<br />including<br />angioedema,<br />urticaria,<br />localized and<br />generalized<br />rash,<br />anaphylaxis</td><td style="width:204px">pruritus</td></tr><tr><td style="width:176px">Metabolism and<br />nutrition<br />disorders</td><td style="width:166px">Timolol<br />maleate eye<br />drops, solution</td><td style="width:64px">&nbsp;</td><td style="width:151px">&nbsp;</td><td style="width:87px">&nbsp;</td><td style="width:187px">&nbsp;</td><td style="width:204px"><br /><br />hypoglycaemia</td></tr><tr><td style="width:176px">Psychiatric<br />disorders<br /><br />&nbsp;</td><td style="width:166px">Timolol<br />maleate eye<br />drops, solution</td><td style="width:64px">&nbsp;</td><td style="width:151px">&nbsp;</td><td style="width:87px">depression*</td><td style="width:187px">insomnia*,<br />nightmares*,<br />memory loss</td><td style="width:204px">&nbsp;</td></tr><tr><td style="width:176px">Nervous system<br />disorders<br /><br />&nbsp;</td><td style="width:166px">Dorzolamide<br />hydrochloride&nbsp;eye drops,<br />solution</td><td style="width:64px">&nbsp;</td><td style="width:151px">headache*</td><td style="width:87px">&nbsp;</td><td style="width:187px">dizziness*,<br />paraesthesia*</td><td style="width:204px">&nbsp;</td></tr><tr><td style="width:176px">&nbsp;</td><td style="width:166px">Timolol<br />maleate eye<br />drops, solution<br />&nbsp;</td><td style="width:64px">&nbsp;</td><td style="width:151px">headache*</td><td style="width:87px">dizziness*,<br />syncope*</td><td style="width:187px">paraesthesia*,<br />increase in signs and symptoms of<br />myasthenia<br />gravis,<br />decreased<br />libido*,<br />cerebrovascular<br />accident*,<br />cerebral<br />ischaemia</td><td style="width:204px">&nbsp;</td></tr><tr><td style="width:176px">Eye disorders</td><td style="width:166px">COSOPT</td><td style="width:64px">burning and<br />stinging<br />&nbsp;</td><td style="width:151px">conjunctival<br />injection,<br />blurred<br />vision,corneal<br />erosion,<br />ocular<br />itching,<br />tearing</td><td style="width:87px">&nbsp;</td><td style="width:187px">&nbsp;</td><td style="width:204px">&nbsp;</td></tr><tr><td style="width:176px">&nbsp;</td><td style="width:166px">Dorzolamide<br />hydrochloride<br />eye drops,<br />solution</td><td style="width:64px">&nbsp;</td><td style="width:151px">eyelid<br />inflammation<br />*, eyelid<br />irritation*</td><td style="width:87px">iridocyclitis*</td><td style="width:187px">irritation<br />including redness*, pain*, eyelid crusting*, transient myopia (which resolved upon discontinuation of therapy),<br />corneal oedema*, ocular hypotony*, choroidal detachment<br />(following filtration surgery)*</td><td style="width:204px">&nbsp;</td></tr><tr><td style="width:176px">&nbsp;</td><td style="width:166px">Timolol<br />maleate eye<br />drops, solution</td><td style="width:64px">&nbsp;</td><td style="width:151px">signs and<br />symptoms of ocular<br />irritation<br />including blepharitis*,<br />keratitis*, decreased corneal sensitivity,<br />and dry eyes*</td><td style="width:87px">visual<br />disturbances<br />including<br />refractive<br />changes (due<br />to withdrawal<br />of miotic<br />therapy in some cases)*</td><td style="width:187px">ptosis, diplopia, choroidal<br />detachment<br />following filtration<br />surgery* (see Special warning and<br />precautions for use 4.4)</td><td style="width:204px">itching, tearing,<br />redness, blurred<br />vision, corneal<br />erosion</td></tr><tr><td style="width:176px">Ear and labyrinth disorders</td><td style="width:166px">Timolol maleate eye drops, solution</td><td style="width:64px">&nbsp;</td><td style="width:151px">&nbsp;</td><td style="width:87px">&nbsp;</td><td style="width:187px">tinnitus*</td><td style="width:204px">&nbsp;</td></tr><tr><td style="width:176px">Cardiac disorders</td><td style="width:166px">Timolol maleate eye drops, solution</td><td style="width:64px">&nbsp;</td><td style="width:151px">&nbsp;</td><td style="width:87px">bradycardia*</td><td style="width:187px">chest pain*, palpitation*,<br />oedema*, arrhythmia*,<br />congestive heart failure*,<br />cardiac arrest*, heart block</td><td style="width:204px">atrioventricular blok,cardiac failure</td></tr><tr><td style="width:176px">Vascular disorders</td><td style="width:166px">Timolol maleate eye<br />drops, solution</td><td style="width:64px">&nbsp;</td><td style="width:151px">&nbsp;</td><td style="width:87px">&nbsp;</td><td style="width:187px">hypotension*, claudication,<br />Raynaud&rsquo;s phenomenon*,<br />cold hands and feet*</td><td style="width:204px">&nbsp;</td></tr><tr><td style="width:176px">Respiratory,<br />thoracic, and mediastinal<br />disorders</td><td style="width:166px">COSOPT</td><td style="width:64px">&nbsp;</td><td style="width:151px">sinusitis</td><td style="width:87px">shortness of<br />breath,respiratory<br />failure, rhinitis,<br />rarely bronchospasm</td><td style="width:187px">&nbsp;</td><td style="width:204px">&nbsp;</td></tr><tr><td style="width:176px">&nbsp;</td><td style="width:166px">Dorzolamide<br />hydrochloride eye drops,<br />solution</td><td style="width:64px">&nbsp;</td><td style="width:151px">&nbsp;</td><td style="width:87px">&nbsp;</td><td style="width:187px">epistaxis*</td><td style="width:204px">&nbsp;</td></tr><tr><td style="width:176px">&nbsp;</td><td style="width:166px">Timololmaleate eye<br />drops, solution</td><td style="width:64px">&nbsp;</td><td style="width:151px">&nbsp;</td><td style="width:87px">dyspnoea*</td><td style="width:187px">bronchospasm<br />(predominantly<br />in patients with pre-existing<br />bronchospastic disease)*,<br />respiratory failure, cough*</td><td style="width:204px">&nbsp;</td></tr><tr><td style="width:176px">Gastrointestinal disorders</td><td style="width:166px">COSOPT</td><td style="width:64px">dysgeusia</td><td style="width:151px">&nbsp;</td><td style="width:87px">&nbsp;</td><td style="width:187px">&nbsp;</td><td style="width:204px">&nbsp;</td></tr><tr><td style="width:176px">&nbsp;</td><td style="width:166px">Dorzolamide<br />hydrochloride<br />eye drops,<br />solution</td><td style="width:64px">&nbsp;</td><td style="width:151px">nausea*</td><td style="width:87px">&nbsp;</td><td style="width:187px">throat irritation, dry mouth*</td><td style="width:204px">&nbsp;</td></tr><tr><td style="width:176px">&nbsp;</td><td style="width:166px">Timolol<br />maleate eye<br />drops, solution</td><td style="width:64px">&nbsp;</td><td style="width:151px">&nbsp;</td><td style="width:87px">nausea*,<br />dyspepsia*</td><td style="width:187px">diarrhoea,<br />dry mouth*</td><td style="width:204px">dysgeusia,<br />abdominal pain,<br />vomiting</td></tr><tr><td style="width:176px">Skin and subcutaneous<br />tissue disorders</td><td style="width:166px">COSOPT</td><td style="width:64px">&nbsp;</td><td style="width:151px">&nbsp;</td><td style="width:87px">&nbsp;</td><td style="width:187px">contact<br />dermatitis,<br />Stevens-<br />Johnson<br />syndrome,<br />toxic epidermal<br />necrolysis</td><td style="width:204px">&nbsp;</td></tr><tr><td style="width:176px">&nbsp;</td><td style="width:166px">Dorzolamide<br />hydrochloride<br />eye drops,<br />solution</td><td style="width:64px">&nbsp;</td><td style="width:151px">&nbsp;</td><td style="width:87px">&nbsp;</td><td style="width:187px">rash*</td><td style="width:204px">&nbsp;</td></tr><tr><td style="width:176px">&nbsp;</td><td style="width:166px">Timolol<br />maleate eye<br />drops, solution</td><td style="width:64px">&nbsp;</td><td style="width:151px">&nbsp;</td><td style="width:87px">&nbsp;</td><td style="width:187px">alopecia*,<br />psoriasiform<br />rash or<br />exacerbation of<br />psoriasis*</td><td style="width:204px">skin rash</td></tr><tr><td style="width:176px">Musculoskeletal<br />and connective tissue disorders</td><td style="width:166px">Timolol<br />maleate eye<br />drops, solution</td><td style="width:64px">&nbsp;</td><td style="width:151px">&nbsp;</td><td style="width:87px">&nbsp;</td><td style="width:187px">systemic lupus<br />erythematosus</td><td style="width:204px">myalgia</td></tr><tr><td style="width:176px">Renal and urinary disorders</td><td style="width:166px">COSOPT</td><td style="width:64px">&nbsp;</td><td style="width:151px">&nbsp;</td><td style="width:87px">urolithiasis</td><td style="width:187px">&nbsp;</td><td style="width:204px">&nbsp;</td></tr><tr><td style="width:176px">Reproductive<br />system and<br />breast disorders</td><td style="width:166px">Timolol<br />maleate eye<br />drops, solution</td><td style="width:64px">&nbsp;</td><td style="width:151px">&nbsp;</td><td style="width:87px">&nbsp;</td><td style="width:187px">Peyronie&rsquo;s<br />disease*,<br />decreased&nbsp;libido</td><td style="width:204px">sexual<br />dysfunction</td></tr><tr><td style="width:176px">General<br />disorders and<br />administration<br />site conditions</td><td style="width:166px">Dorzolamide<br />hydrochloride<br />eye drops,<br />solution</td><td style="width:64px">&nbsp;</td><td style="width:151px">asthenia/<br />fatigue*</td><td style="width:87px">&nbsp;</td><td style="width:187px">&nbsp;</td><td style="width:204px">&nbsp;</td></tr><tr><td style="width:176px">&nbsp;</td><td style="width:166px">Timolol<br />maleate eye<br />drops, solution</td><td style="width:64px">&nbsp;</td><td style="width:151px">&nbsp;</td><td style="width:87px">asthenia/<br />fatigue*</td><td style="width:187px">&nbsp;</td><td style="width:204px">&nbsp;</td></tr><tr><td style="width:176px">&nbsp;</td><td style="width:166px">&nbsp;</td><td style="width:64px">&nbsp;</td><td style="width:151px">&nbsp;</td><td style="width:87px">&nbsp;</td><td style="width:187px">&nbsp;</td><td style="width:204px">&nbsp;</td></tr></tbody></table><p>*These adverse reactions were also observed with COSOPT during post-marketing experience.<br />**Additional adverse reactions have been seen with ophthalmic beta-blockers and may potentially occur with COSOPT.</p><p>Reporting of suspected adverse reactions<br />Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare<br />professionals are asked to report any suspected adverse reactions via the &ldquo;The National Pharmacovigilance and Drug Safety Centre (NPC)&rdquo;.</p><p>Saudi Arabia:<br />The National Pharmacovigilance and Drug Safety Centre (NPC)<br />o Fax: +966-11-205-7662<br />o Call NPC at +966-11-20382222, Exts: 2317-2356-2353-2354-2334-2340.<br />o Toll free phone: 8002490000<br />o E-mail: npc.drug@sfda.gov.sa<br />o Website: www.sfda.gov.sa/npc</p><p><br /> Other GCC States:<br />Please contact the relevant competent authority.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No data are available in humans in regard to overdose by accidental or deliberate ingestion of COSOPT.</p><p><u>Symptoms</u><br />There have been reports of inadvertent overdoses with timolol maleate ophthalmic solution resulting in systemic effects similar to those seen with systemic beta-adrenergic blocking agents such as dizziness,<br />headache, shortness of breath, bradycardia, bronchospasm, and cardiac arrest. The most common signs and symptoms to be expected with overdoses of dorzolamide are electrolyte imbalance, development<br />of an acidotic state, and possibly central nervous system effects.</p><p>Only limited information is available with regard to human overdose by accidental or deliberate ingestion of dorzolamide hydrochloride. With oral ingestion, somnolence has been reported. With topical application the following have been reported: nausea, dizziness, headache, fatigue, abnormal dreams, and dysphagia.</p><p><u>Treatment</u><br />Treatment should be symptomatic and supportive. Serum electrolyte levels (particularly potassium) and blood pH levels should be monitored. Studies have shown that timolol does not dialyze readily.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antiglaucoma preparations and miotics, Beta blocking agents, Timolol, combinations, ATC code: S01ED51</p><p><br /><u>Mechanism of action</u><br />COSOPT is comprised of two components: dorzolamide hydrochloride and timolol maleate. Each of these two components decreases elevated intraocular pressure by reducing aqueous humor secretion, but does so by a different mechanism of action.</p><p>Dorzolamide hydrochloride is a potent inhibitor of human carbonic anhydrase II. Inhibition of carbonic anhydrase in the ciliary processes of the eye decreases aqueous humor secretion, presumably by slowing the formation of bicarbonate ions with subsequent reduction in sodium and fluid transport. Timolol maleate is a nonselective beta-adrenergic receptor blocking agent. The precise mechanism of action of timolol maleate in lowering intraocular pressure is not clearly established at this time, although a fluorescein study and tonography studies indicate that the predominant action may be related to reduced aqueous formation. However, in some studies a slight increase in outflow facility was also observed. The combined effect of these two agents results in additional intraocular pressure reduction (IOP) compared to either component administered alone.</p><p>Following topical administration, this medicinal product reduces elevated intraocular pressure, whether or not associated with glaucoma. Elevated intraocular pressure is a major risk factor in the pathogenesis of optic nerve damage and glaucomatous visual field loss. This medicinal product reduces intraocular pressure without the common side effects of miotics such as night blindness, accommodative spasm and pupillary constriction.</p><p><u>Pharmacodynamic effects</u></p><p><br /><em>Clinical Effects</em><br />Clinical studies of up to 15 months duration were conducted to compare the IOP-lowering effect of COSOPT b.i.d. (dosed morning and bedtime) to individually- and concomitantly-administered 0.5%<br />timolol and 2.0% dorzolamide in patients with glaucoma or ocular hypertension for whom concomitant therapy was considered appropriate in the trials. This included both untreated patients and<br />patients inadequately controlled with timolol monotherapy. The majority of patients were treated with topical beta-blocker monotherapy prior to study enrollment. In an analysis of the combined studies, the<br />IOP-lowering effect of COSOPT b.i.d. was greater than that of monotherapy with either 2% dorzolamide t.i.d. or 0.5% timolol b.i.d. The IOP-lowering effect of COSOPT b.i.d. was equivalent to<br />that of concomitant therapy with dorzolamide b.i.d. and timolol b.i.d. The IOP-lowering effect of COSOPT b.i.d. was demonstrated when measured at various time points throughout the day and this effect was maintained during long-term administration.</p><p><u>Paediatric population</u><br />A 3 month controlled study, with the primary objective of documenting the safety of 2% dorzolamide hydrochloride ophthalmic solution in children under the age of 6 years has been conducted. In this<br />study, 30 patients under 6 and greater than or equal to 2 years of age whose IOP was not adequately controlled with monotherapy by dorzolamide or timolol received COSOPT in an open label phase. Efficacy in those patients has not been established. In this small group of patients, twice daily administration of COSOPT was generally well tolerated with 19 patients completing the treatment period and 11 patients discontinuing for surgery, a change in medication, or other reasons.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Dorzolamide Hydrochloride</u><br />Unlike oral carbonic anhydrase inhibitors, topical administration of dorzolamide hydrochloride allows for the active substance to exert its effects directly in the eye at substantially lower doses and therefore with less systemic exposure. In clinical trials, this resulted in a reduction in IOP without the acid-base disturbances or alterations in electrolytes characteristic of oral carbonic anhydrase inhibitors.</p><p><br />When topically applied, dorzolamide reaches the systemic circulation. To assess the potential for systemic carbonic anhydrase inhibition following topical administration, active substance and metabolite concentrations in red blood cells (RBCs) and plasma and carbonic anhydrase inhibition in RBCs were measured. Dorzolamide accumulates in RBCs during chronic dosing as a result of selective binding to CA-II while extremely low concentrations of free active substance in plasma are maintained. The parent active substance forms a single N-desethyl metabolite that inhibits CA-II lesspotently than the parent active substance but also inhibits a less active isoenzyme (CA-I). The metabolite also accumulates in RBCs where it binds primarily to CA-I. Dorzolamide binds moderately to plasma proteins (approximately 33%). Dorzolamide is primarily excreted unchanged in the urine; the metabolite is also excreted in urine. After dosing ends, dorzolamide washes out of RBCs nonlinearly, resulting in a rapid decline of active substance concentration initially, followed by a slower elimination phase with a half-life of about four months.</p><p><br />When dorzolamide was given orally to simulate the maximum systemic exposure after long term topical ocular administration, steady state was reached within 13 weeks. At steady state, there was<br />virtually no free active substance or metabolite in plasma; CA inhibition in RBCs was less than that anticipated to be necessary for a pharmacological effect on renal function or respiration. Similar<br />pharmacokinetic results were observed after chronic, topical administration of dorzolamide hydrochloride. However, some elderly patients with renal impairment (estimated CrCl 30-60 ml/min) had higher metabolite concentrations in RBCs, but no meaningful differences in carbonic anhydrase inhibition and no clinically significant systemic side effects were directly attributable to this finding.</p><p><u>Timolol Maleate</u><br />In a study of plasma active substance concentration in six subjects, the systemic exposure to timolol was determined following twice daily topical administration of timolol maleate ophthalmic solution<br />0.5%. The mean peak plasma concentration following morning dosing was 0.46 ng/ml and following afternoon dosing was 0.35 ng/ml.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The ocular and systemic safety profile of the individual components is well established.</p><p><br />Dorzolamide<br />In rabbits given maternotoxic doses of dorzolamide associated with metabolic acidosis, malformations of the vertebral bodies were observed.</p><p><br />Timolol<br />Animal studies have not shown teratogenic effect.</p><p><br />Furthermore, no adverse ocular effects were seen in animals treated topically with dorzolamide hydrochloride and timolol maleate ophthalmic solution or with concomitantly-administered<br />dorzolamide hydrochloride and timolol maleate. In vitro and in vivo studies with each of the components did not reveal a mutagenic potential. Therefore, no significant risk for human safety is expected with therapeutic doses of COSOPT.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Benzalkonium chloride<br />Hydroxyethyl cellulose<br />Mannitol (E421)<br />Sodium citrate dihydrate (E331)<br />Sodium hydroxide (E524) for pH adjustment<br />Water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years
COSOPT should be used no longer than 28 days after first opening the container.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C<br />Store in the original package in order to protect from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The OCUMETER Plus Ophthalmic Dispenser consists of a translucent, high-density polyethylene container with a sealed dropper tip, a flexible fluted side area which is depressed to dispense the drops,<br />and a 2-piece cap assembly. The 2-piece cap mechanism punctures the sealed dropper tip upon initial use, then locks together to provide a single cap during the usage period. Tamper evidence is provided<br />by a safety strip on the container label. The OCUMETER Plus Ophthalmic Dispenser contains 5 ml of solution.</p><p>COSOPT is available in the following packaging configurations:<br />1 x 5 ml (single 5 ml containers)<br />3 x 5 ml (three 5 ml containers)<br />6 x 5 ml (six 5 ml containers)<br />Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Merck Sharp & Dohme B.V., Waarderweg 39,
2031 BN Haarlem, P.O. Box 581, 2003 PC Haarlem,
The Netherlands

Manufacturer
Laboratoires Merck Sharp & Dohme Chibret, Mirabel Plant, Route de Marsat, Riom, 63963 Clermont-Ferrand
Cedex 9 , France
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Last partial revision concerns sections 4.2, 4.3, 4.4, 4.8 and 5.2: 21 March 2014.
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>